Costs and cost-effectiveness of the Kerala pilot screening programme for diabetic retinopathy in the public health system.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
received:
15
08
2023
accepted:
12
08
2024
revised:
29
07
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
3
9
2024
Statut:
aheadofprint
Résumé
The Government of Kerala initiated a pilot screening programme for diabetic retinopathy in 16 Family Health Centres in Thiruvananthapuram district in 2019 in collaboration with the ORNATE India project. The evaluation of this pilot included a study of its costs and cost-effectiveness to inform decisions about extending the programme throughout Kerala. The participants comprise all 5307 people who were screened for diabetic retinopathy under the pilot programme for whom data could be collected. The costs of the pilot programme are estimated at INR 11.3 million (including INR 1.9 million costs to individuals) and the benefits at 514 QALYs, slightly over one QALY per person treated. The cost per QALY was INR 22,000, which is well below India's Gross National Income per person. Kerala's 2019 pilot screening programme for diabetic retinopathy was highly cost-effective.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
The Government of Kerala initiated a pilot screening programme for diabetic retinopathy in 16 Family Health Centres in Thiruvananthapuram district in 2019 in collaboration with the ORNATE India project. The evaluation of this pilot included a study of its costs and cost-effectiveness to inform decisions about extending the programme throughout Kerala.
SUBJECTS/METHODS
METHODS
The participants comprise all 5307 people who were screened for diabetic retinopathy under the pilot programme for whom data could be collected.
RESULTS
RESULTS
The costs of the pilot programme are estimated at INR 11.3 million (including INR 1.9 million costs to individuals) and the benefits at 514 QALYs, slightly over one QALY per person treated. The cost per QALY was INR 22,000, which is well below India's Gross National Income per person.
CONCLUSIONS
CONCLUSIONS
Kerala's 2019 pilot screening programme for diabetic retinopathy was highly cost-effective.
Identifiants
pubmed: 39227383
doi: 10.1038/s41433-024-03304-w
pii: 10.1038/s41433-024-03304-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Wong TY, Sabanayagam C. Strategies to tackle the global burden of diabetic retinopathy: from epidemiology to artificial intelligence. Ophthalmologica. 2020;243:9–20.
doi: 10.1159/000502387
pubmed: 31408872
Federation I IDF Diabetes Atlas, 9th edn. 2019.
Raman R, Gella L, Srinivasan S, Sharma T. Diabetic retinopathy: An epidemic at home and around the world. Indian J Ophthalmol. 2016;64:69.
doi: 10.4103/0301-4738.178150
pubmed: 26953027
pmcid: 4821125
Redding S, Anderson R, Raman R, Sivaprasad S, Wittenberg R, Group OIP. Estimating the costs of blindness and moderate to severe visual impairment among people with diabetes in India. BMJ Open. 2023;13:e063390.
doi: 10.1136/bmjopen-2022-063390
pubmed: 37355259
pmcid: 10314483
Shukla R, Gudlavalleti MV, Bandyopadhyay S, Anchala R, Gudlavalleti ASV, Jotheeswaran A, et al. Perception of care and barriers to treatment in individuals with diabetic retinopathy in India: 11-city 9-state study. Indian J Endocrinol Metab. 2016;20:S33.
doi: 10.4103/2230-8210.179772
pubmed: 27144135
pmcid: 4847448
Sivaprasad S, Netuveli G, Wittenberg R, Khobragade R, Sadanandan R, Gopal B, et al. Complex interventions to implement a diabetic retinopathy care pathway in the public health system in Kerala: the Nayanamritham study protocol. BMJ Open. 2021;11:e040577.
doi: 10.1136/bmjopen-2020-040577
pubmed: 34183333
pmcid: 8240569
IIPS. National Family Health Survey-5 (2019-20): State Fact Sheet Kerala. International Institute for Population Sciences Mumbai; 2021.
Sivaprasad S, Raman R, Conroy D, Wittenberg R, Rajalakshmi R, Majeed A, et al. The ORNATE India Project: United Kingdom–India Research Collaboration to tackle visual impairment due to diabetic retinopathy. Eye. 2020;34:1279–86.
doi: 10.1038/s41433-020-0854-8
pubmed: 32398841
pmcid: 7314790
Brown GC. Vision and quality-of-life. Am J Ophthalmol. 2000;129:833.
doi: 10.1016/S0002-9394(00)00513-4
pubmed: 10927011
Pennington B, Alshreef A, Flight L, Metry A, Poku E, Hykin P, et al. Cost effectiveness of ranibizumab vs. aflibercept vs. bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study. Pharmacoeconomics. 2021;39:913–27.
doi: 10.1007/s40273-021-01026-5
pubmed: 33900585
pmcid: 8298346
Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The cost–utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology. 2013;120:566–73.
doi: 10.1016/j.ophtha.2012.09.002
pubmed: 23211635
Office of the Registrar General & Census Commissioner I. Life Tables India 2006-10.
Brown G. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473–511.
pubmed: 10703139
pmcid: 1298275
Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Mak. 2006;26:391–400.
doi: 10.1177/0272989X06290497
Song E, Sun H, Xu Y, Ma Y, Zhu H, Pan C-W. Age-related cataract, cataract surgery and subsequent mortality: a systematic review and meta-analysis. PLoS ONE. 2014;9:e112054.
doi: 10.1371/journal.pone.0112054
pubmed: 25369040
pmcid: 4219834
Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ. 2014;93:118–24.
doi: 10.2471/BLT.14.138206
pubmed: 25883405
pmcid: 4339959
Pasquel FJ, Hendrick AM, Ryan M, Cason E, Ali MK, Narayan KV. Cost-effectiveness of different diabetic retinopathy screening modalities. J diabetes Sci Technol. 2016;10:301–7.
doi: 10.1177/1932296815624109
Bascaran C, Mwangi N, D’Esposito F, Gordon I, Ulloa JAL, Mdala S, et al. Effectiveness of task-shifting for the detection of diabetic retinopathy in low-and middle-income countries: a rapid review protocol. Syst Rev. 2021;10:1–5.
Yim D, Chandra S, Sondh R, Thottarath S, Sivaprasad S. Barriers in establishing systematic diabetic retinopathy screening through telemedicine in low-and middle-income countries. Indian J Ophthalmol. 2021;69:2987.
doi: 10.4103/ijo.IJO_1411_21
pubmed: 34708733
pmcid: 8725078
Khan T, Bertram MY, Jina R, Mash B, Levitt N, Hofman K. Preventing diabetes blindness: cost effectiveness of a screening programme using digital non-mydriatic fundus photography for diabetic retinopathy in a primary health care setting in South Africa. Diabetes Res Clin Pract. 2013;101:170–6.
doi: 10.1016/j.diabres.2013.05.006
pubmed: 23796361
Vetrini D, Kiire CA, Burgess PI, Harding SP, Kayange PC, Kalua K, et al. Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi. PLoS ONE. 2018;13:e0190742.
doi: 10.1371/journal.pone.0190742
pubmed: 29300755
pmcid: 5754125